Propublica, a nonprofit investigative reporting organization, published a carefully-researched article on kidney dialysis in the
last week. The article will be in next month’s Atlantic magazine, and I learned about it from an interview on NPR’s Fresh Air. United States
We initiate dialysis a lot of people in the
– more proportionately than any other developed country. We’re obese and getting more so, and diabetes is a major cause of renal failure. Renal failure disproportionately afflicts African-Americans and the poor; part of this is because those with poor access to health care are more likely to have uncontrolled high blood pressure. However, our patients on dialysis die more quickly than those in other countries -- United States
The article focuses on the poor care offered in the
compared to other developed countries. Reporter Robin Fields documents renal failure patients who exanguinated when their dialysis catheters were hooked up incorrectly, and centers that were repeatedly cited for safety violations. She points out that in other countries kidney failure patients get longer dialysis, and have more physician supervision. US
No surprise – we spend a lot of money on dialysis too. On average, we spend $77,000 on dialysis per patient per year – more than any other country
Here’s the surprise. We spend less per dialysis session than all other developed countries except
- $121 per session in 2003 - even though the resource cost to deliver dialysis is substantially higher. Australia
How could it be that in a country where unit price is almost always the problem, we are paying such a low unit price for dialysis?
Well – this price is set by the US Congress – which has been aghast at the total cost of dialysis, about $20 billion per year. Congress lowered the price per session in the 1980s after noting very high margins for dialysis providers. The two companies that dominate the dialysis industry remain very profitable.
AND while the unit price is low, the aggregate cost of dialysis per patient per year is much higher than elsewhere. How can this be?
, we pay a single price for the dialysis, and we pay separately for medications that are administered intravenously during the dialysis. This has meant that dialysis units facing a large cut in their reimbursement for their core service were able to be profitable by administering large doses of erythropoietin (epo), a medicine to combat the anemia associated with renal failure. US
As a result, the
has used far more epo than other countries – good news for Amgen, the manufacturer. This has been bad news for patients, though, as we’ve learned that higher doses of this medicine don’t simply mean less anemia, they also cause higher risk of heart attacks and strokes. US
CMS has announced a new plan to bundle payments for dialysis. The total stated cost will be higher –but the dialysis center will no longer be able to gain margin from administration of medications. That’s good news.
As the Congress debates legislation that would once again reverse the physician SGR (sustainable growth revenue) 23% Medicare physician fee cut, it’s important to remember that too low a price in a fee for service world can lead to overutilization of other services. Simply cutting prices can lead to results that can be expensive, and can hurt patients.
These graphics and data for top graphic are from this article in the International Journal of Health Care Finance 2007. Click images to enlarge